{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:40:22Z","timestamp":1793072422558,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172564"],"award-info":[{"award-number":["82172564"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303032"],"award-info":[{"award-number":["82303032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy has emerged as a promising approach in prostate cancer treatment, albeit with less efficacy compared to lung and esophageal cancers. Recent studies have explored the combination of chemotherapy, specifically docetaxel, with immunotherapy to enhance treatment outcomes. Docetaxel has been reported to be associated with the pyroptosis pathway, which can alter the tumor microenvironment. Therefore, we attempted to explore the specific molecular mechanism by which docetaxel enhances immunotherapy, with the aim of providing new insights for the immunotherapy of prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Immunohistochemical analysis was employed to assess changes in immune markers in prostate cancer tissues pre- and post-docetaxel treatment. Functional assays, including LDH release and flow cytometry, validated cell responses. Molecular interactions were investigated using co-immunoprecipitation and GST pull-down assays to elucidate the binding mechanism between GSDME and SKP2. The detailed mechanism of GSDME activating cellular immunity was analyzed by single cell sequencing. A xenograft model was utilized to confirm the therapeutic efficacy and molecular role of docetaxel combined with immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Docetaxel chemotherapy increased immune-related lymphocytes in patient samples, suggesting an enhanced immune response. Furthermore, docetaxel induced pyroptosis in prostate cancer cells via the GSDME pathway, influencing the immune microenvironment without affecting cell viability. GSDME was found to undergo SKP2-mediated ubiquitination and degradation via the proteasome pathway, this process can be blocked by the inhibition of GSDME phosphorylation through the AKT pathway mediated by docetaxel. The results of single-cell sequencing suggest that GSDME can recruit CD8\u2009+\u2009T lymphocytes and NK cells in prostate cancer. The experimental data indicate that the combination of docetaxel and avelumab can achieve better therapeutic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that docetaxel enhances immunotherapy efficacy in prostate cancer by modulating pyroptosis pathways. This approach may offer a novel therapeutic strategy for clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03614-1","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:47:55Z","timestamp":1766036875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells"],"prefix":"10.1186","volume":"45","author":[{"given":"Ruoyang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyue","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhankui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"3614_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3614_CR2","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.ymthe.2021.04.029","volume":"29","author":"Y Xu","year":"2021","unstructured":"Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, et al. The roles of PD-1\/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther. 2021;29(6):1958\u201369.","journal-title":"Mol Ther"},{"issue":"10305","key":"3614_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021;398(10305):1075\u201390.","journal-title":"Lancet"},{"issue":"4","key":"3614_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Cancer Discov"},{"issue":"6","key":"3614_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","volume":"53","author":"E Bonavita","year":"2020","unstructured":"Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity. 2020;53(6):1215-29.e8.","journal-title":"Immunity"},{"issue":"8","key":"3614_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/cac2.12295","volume":"42","author":"AA Bhat","year":"2022","unstructured":"Bhat AA, Nisar S, Singh M, Ashraf B, Masoodi T, Prasad CP, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy. Cancer Commun (Lond). 2022;42(8):689\u2013715.","journal-title":"Cancer Commun (Lond)"},{"issue":"8","key":"3614_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","volume":"43","author":"RC Coll","year":"2022","unstructured":"Coll RC, Schroder K, Pelegr\u00edn P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022;43(8):653\u201368.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"3614_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","volume":"20","author":"P Broz","year":"2020","unstructured":"Broz P, Pelegr\u00edn P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020;20(3):143\u201357.","journal-title":"Nat Rev Immunol"},{"issue":"7661","key":"3614_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99\u2013103.","journal-title":"Nature"},{"issue":"1","key":"3614_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13046-023-02876-x","volume":"42","author":"K Wimmer","year":"2023","unstructured":"Wimmer K, Sachet M, Ramos C, Frantal S, Birnleitner H, Brostjan C, et al. Differential immunomodulatory effects of epirubicin\/cyclophosphamide and docetaxel in breast cancer patients. J Exp Clin Cancer Res. 2023;42(1):300.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3614_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-019-0511-6","volume":"7","author":"Q Gao","year":"2019","unstructured":"Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, et al. Cancer-cell-secreted CXCL11 promoted CD8(+) T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer. 2019;7(1):42.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3614_CR12","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s10637-020-00922-5","volume":"38","author":"HA Maulhardt","year":"2020","unstructured":"Maulhardt HA, Marin AM, diZerega GS. Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood. Invest New Drugs. 2020;38(5):1618\u201326.","journal-title":"Invest New Drugs"},{"issue":"11","key":"3614_CR13","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","volume":"14","author":"CT Garnett","year":"2008","unstructured":"Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536\u201344.","journal-title":"Clin Cancer Res"},{"issue":"Pt 2","key":"3614_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2020.01.013","volume":"67","author":"Z Cai","year":"2020","unstructured":"Cai Z, Moten A, Peng D, Hsu CC, Pan BS, Manne R, et al. The Skp2 pathway: a critical target for cancer therapy. Semin Cancer Biol. 2020;67(Pt 2):16\u201333.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"3614_CR15","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/med.21675","volume":"40","author":"MD Asmamaw","year":"2020","unstructured":"Asmamaw MD, Liu Y, Zheng YC, Shi XJ, Liu HM. Skp2 in the ubiquitin-proteasome system: a comprehensive review. Med Res Rev. 2020;40(5):1920\u201349.","journal-title":"Med Res Rev"},{"issue":"4","key":"3614_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ. Doubletfinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 2019;8(4):329-37.e4.","journal-title":"Cell Syst"},{"issue":"1","key":"3614_CR17","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1093\/nar\/gkad1032","volume":"52","author":"Y Yin","year":"2024","unstructured":"Yin Y, Yajima M, Campbell JD. Characterization and decontamination of background noise in droplet-based single-cell protein expression data with DecontPro. Nucleic Acids Res. 2024;52(1):e4.","journal-title":"Nucleic Acids Res"},{"key":"3614_CR18","doi-asserted-by":"crossref","unstructured":"Sheng D, Ma W, Zhang R, Zhou L, Deng Q, Tu J, et al. Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization. J Immunother Cancer. 2022;10(5):e003793.","DOI":"10.1136\/jitc-2021-003793"},{"key":"3614_CR19","doi-asserted-by":"publisher","first-page":"111015","DOI":"10.1016\/j.cellsig.2023.111015","volume":"114","author":"X Liu","year":"2024","unstructured":"Liu X, Wang B, Chang M, Zhang X, Zou H, Zhang Z, et al. USP12 regulates ER stress-associated osteogenesis in human periodontal ligament cells under tension stress. Cell Signal. 2024;114:111015.","journal-title":"Cell Signal"},{"issue":"6","key":"3614_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrc2396","volume":"8","author":"D Frescas","year":"2008","unstructured":"Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8(6):438\u201349.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3614_CR21","first-page":"1067","volume":"41","author":"X Zhang","year":"2019","unstructured":"Zhang X, Shao J, Li X, Cui L, Tan Z. Docetaxel promotes cell apoptosis and decreases SOX2 expression in CD133-expressing hepatocellular carcinoma stem cells by suppressing the PI3K\/AKT signaling pathway. Oncol Rep. 2019;41(2):1067\u201374.","journal-title":"Oncol Rep"},{"issue":"3","key":"3614_CR22","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/bcr2252","volume":"11","author":"J Kalra","year":"2009","unstructured":"Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, et al. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 2009;11(3):R25.","journal-title":"Breast Cancer Res"},{"key":"3614_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lfs.2016.08.019","volume":"162","author":"S Erdogan","year":"2016","unstructured":"Erdogan S, Doganlar O, Doganlar ZB, Serttas R, Turkekul K, Dibirdik I, et al. The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K\/Akt\/NF-\u03baB signaling. Life Sci. 2016;162:77\u201386.","journal-title":"Life Sci"},{"issue":"12","key":"3614_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41422-023-00848-6","volume":"33","author":"YL Ai","year":"2023","unstructured":"Ai YL, Wang WJ, Liu FJ, Fang W, Chen HZ, Wu LZ, et al. Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P. Cell Res. 2023;33(12):904\u201322.","journal-title":"Cell Res"},{"issue":"1","key":"3614_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"3614_CR26","doi-asserted-by":"publisher","first-page":"101199","DOI":"10.1016\/j.xcrm.2023.101199","volume":"4","author":"D Sridaran","year":"2023","unstructured":"Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K, Mahajan NP. Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach. Cell Rep Med. 2023;4(10):101199.","journal-title":"Cell Rep Med"},{"key":"3614_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2021.09.043","volume":"160","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Gonz\u00e1lez Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, et al. Nivolumab plus docetaxel in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2022;160:61\u201371.","journal-title":"Eur J Cancer"},{"issue":"11","key":"3614_CR28","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"Z Ma","year":"2022","unstructured":"Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R, et al. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics. 2022;12(11):4965\u201379.","journal-title":"Theranostics"},{"issue":"10","key":"3614_CR29","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","volume":"13","author":"JE Cortes","year":"1995","unstructured":"Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643\u201355.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3614_CR30","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","volume":"18","author":"D Bertheloot","year":"2021","unstructured":"Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol. 2021;18(5):1106\u201321.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"3614_CR31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.7150\/ijbs.41686","volume":"16","author":"X Lu","year":"2020","unstructured":"Lu X, Yang F, Chen D, Zhao Q, Chen D, Ping H, et al. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K\/Akt signaling pathways. Int J Biol Sci. 2020;16(7):1121\u201334.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"3614_CR32","first-page":"3864","volume":"19","author":"C Yang","year":"2019","unstructured":"Yang C, Zhang W, Wang J, Chen P, Jin J. Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells. Mol Med Rep. 2019;19(5):3864\u201370.","journal-title":"Mol Med Rep"},{"issue":"13","key":"3614_CR33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330.","journal-title":"N Engl J Med"},{"issue":"11","key":"3614_CR34","doi-asserted-by":"publisher","first-page":"e1466018","DOI":"10.1080\/2162402X.2018.1466018","volume":"7","author":"KC Hicks","year":"2018","unstructured":"Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, et al. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. Oncoimmunology. 2018;7(11):e1466018.","journal-title":"Oncoimmunology"},{"issue":"4","key":"3614_CR35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/ncb1849","volume":"11","author":"HK Lin","year":"2009","unstructured":"Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, et al. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt\/PKB. Nat Cell Biol. 2009;11(4):420\u201332.","journal-title":"Nat Cell Biol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03614-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:20:34Z","timestamp":1781623234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03614-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3614"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03614-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures and use of human specimens were approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2024-KY-0595).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All co-authors have consented the version of manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}